03/2020. Chinese Patent Granted
The Chinese Patent Office (CNIPA) has granted the patent CN105492022B «Immunogenic complex for vaccination and method for the production thereof» to INMUNOTEK.
The invention relates to hypoallergenic polymerized neoglycoconjugates (allergoids-mannan) developed for the design of new anti-allergy vaccines targeting dendritic cells. This patent is in addition to those already granted by Japan, US and Mexico for said composition.
The conjugation of allergoids with mannan improves the bioavailability of the vaccine to dendritic cells while favoring the induction of regulatory T cells, essential to achieve the desired tolerance against the allergen.
The invention is the result of an INMUNOTEK research project that has received funding from the Center for Industrial Technological Development (CDTI, Spain) and the collaboration of researchers from the CIB-CSIC and Complutense University (Madrid).
References:
Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines. Manzano AI, Javier Cañada F, Cases B, Sirvent S, Soria I, Palomares O, Fernández-Caldas E, Casanovas M, Jiménez-Barbero J, Subiza JL. Glycoconj J. 2016 Feb;33(1):93-101. doi: 10.1007/s10719-015-9640-4. Epub 2015 Nov 25.
Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1. Sirvent S, Soria I, Cirauqui C, Cases B, Manzano AI, Diez-Rivero CM, Reche PA, López-Relaño J, Martínez-Naves E, Cañada FJ, Jiménez-Barbero J, Subiza J, Casanovas M, Fernández-Caldas E, Subiza JL, Palomares O. J Allergy Clin Immunol. 2016 Aug;138(2):558-567.e11. doi: 10.1016/j.jaci.2016.02.029. Epub 2016 Apr 13
Dendritic cell targeting with C-type lectins for improvement of allergen immunotherapy. Schülke S, Vieths S. J Allergy Clin Immunol. 2016 Aug;138(2):568-70. doi: 10.1016/j.jaci.2016.06.006. Epub 2016 Jun 23.
Human basophils may not undergo modulation by DC-SIGN and mannose receptor–targeting immunotherapies due to absence of receptors. Das M, Galeotti C, Stephen-Victor E, Karnam A, Kaveri SV, Bayry J. J Allergy Clin Immunol. 2017 Apr;139(4):1403-1404.e1. doi: 10.1016/j.jaci.2016.09.062. Epub 2017 Jan 11.
Mite allergoids coupled to nonoxidized mannan from Saccharomyces cerevisae efficiently target canine dendritic cells for novel allergy immunotherapy in veterinary medicine. Soria I, Alvarez J, Manzano AI, López-Relaño J, Cases B, Mas-Fontao A, Cañada FJ, Fernández-Caldas E, Casanovas M, Jiménez-Barbero J, Palomares O, Viñals-Flórez LM, Subiza JL. Vet Immunol Immunopathol. 2017 Aug;190:65-72. doi: 10.1016/j.vetimm.2017.07.004. Epub 2017 Jul 23.
Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice. Soria I, López-Relaño J, Viñuela M, Tudela JI, Angelina A, Benito-Villalvilla C, Díez-Rivero CM, Cases B, Manzano AI, Fernández-Caldas E, Casanovas M, Palomares O, Subiza JL. Allergy. 2018 Apr;73(4):875-884. doi: 10.1111/all.13396. Epub 2018 Jan 31.
Novel vaccines targeting dendritic cells by coupling allergoids to mannan. Benito-Villalvilla, C., Soria, I., Subiza, J.L. et al. Allergo J Int (2018). https://doi.org/10.1007/s40629-018-0069-8
A pilot study of immunotherapy in dogs with atopic dermatitis using a mannan‐Dermatophagoides farinae allergoid targeting dendritic cells. González, J.‐L., Zalve, V., Fernández‐Caldas, E., Cases, B., Subiza, J.‐L. and Casanovas, M. (2018) Vet Dermatol, 29: 449-e152. https://doi.org/10.1111/vde.12679
Alum impairs tolerogenic properties induced by allergoid‐mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs. Benito‐Villalvilla, C, Soria, I, Pérez‐Diego, M, Fernández‐Caldas, E, Subiza, JL, Palomares, O. (2019) Allergy. 75: 648– 659. https://doi.org/10.1111/all.14036
